These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 10073279

  • 1. Immunologic therapy of multiple sclerosis.
    Arnason BG.
    Annu Rev Med; 1999; 50():291-302. PubMed ID: 10073279
    [Abstract] [Full Text] [Related]

  • 2. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T, Bereczki D.
    Ideggyogy Sz; 2004 Nov 20; 57(11-12):401-16. PubMed ID: 15662768
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P.
    Expert Rev Neurother; 2004 May 20; 4(3):455-63. PubMed ID: 15853542
    [Abstract] [Full Text] [Related]

  • 8. Rationale and design of the prospective and retrospective observational study of Avonex and Rebif (PROOF) for the treatment of relapsing-remitting multiple sclerosis.
    Murray TJ.
    Curr Med Res Opin; 2004 Jan 20; 20(1):25-30. PubMed ID: 14741068
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Biogen wins Euro MS approval, but loses patents.
    Brower V.
    Nat Biotechnol; 1997 May 20; 15(5):410. PubMed ID: 9131611
    [No Abstract] [Full Text] [Related]

  • 11. Interferon beta treatment for multiple sclerosis: persisting questions.
    Goodkin DE.
    Mult Scler; 1996 Jul 20; 1(6):321-4. PubMed ID: 9345408
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR, Panitch HS.
    Clin Ther; 2007 Sep 20; 29(9):2031-48. PubMed ID: 18035202
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.